^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersBIOMARKER:
HER-2 negative + CLDN18.2 positive
i
Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; CLDN18, Claudin-18, Surfactant, Pulmonary Associated Protein J, Surfactant Associated 5, SFTA5, SFTPJ
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
2ms
Osemitamab (TST001) plus nivolumab and CAPOX as the first-line therapy for the patients with advanced G/GEJ cancer (TranStar102) (ESMO 2024)
Updated data indicate that the combination of TST001 plus nivolumab and CAPOX as the 1L treatment for patients with G/GEJ cancer is safe and well tolerated with very encouraging anti-tumor activities, especially for patients with high/medium CLDN18.2 expression when cross comparing to historical data.
Clinical • PD(L)-1 Biomarker • IO biomarker • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • CLDN18 (Claudin 18)
|
PD-L1 expression • HER-2 negative • CLDN18.2 expression • CLDN18.2 positive • HER-2 negative + CLDN18.2 positive
|
PD-L1 IHC 28-8 pharmDx • Claudin18.2 IHC 14G11 pharmDx
|
Opdivo (nivolumab) • osemitamab (TST001)
Share via
